saw its Q4FY26 net profit after tax decline sharply to ₹2.17 crore, down 70 per cent year-on-year. FY26 PAT (post non-controlling interest) was normalised for one-time exceptional items related to the impact of the new labour code (₹12.7 crore, with a post-tax impact of around ₹10 crore) and goodwill impairment in the fertility business (₹31.9 crore).
Volumes grew around 13 per cent year-on-year during the quarter, reflecting continued momentum across clusters and healthy underlying demand. However, ARPP moderated due to clinical transitions in Kolkata, which impacted the case mix.
Revenue for the quarter stood at ₹650.29 crore, up 11.4 per cent year-on-year.
Dr B S Ajaikumar said: “As we look ahead, our focus is on strengthening next-generation oncology capabilities across precision medicine, molecular diagnostics, genomics, robotics and data-driven clinical decision-making. These advancements will play a critical role in detecting cancer earlier, reducing recurrence, improving outcomes and making personalised cancer care more accessible to patients across India.”
Commenting on the results, Dr Manish Mattoo said the performance demonstrates the scalability of the company’s model and the depth of its clinical capabilities, backed by a sustained focus on outcomes and patient-centric care.
“A key milestone during the year was the successful completion of our ₹425 crore rights issue, which further strengthened our financial foundation and gives us greater flexibility to invest in our long-term priorities, including capacity expansion, clinical infrastructure upgrades, technology investments, and selective growth opportunities,” he said.
The company said it is evaluating an alternate location for its Whitefield hospital, which would offer comprehensive cancer services. The hospital is anticipated to become operational by FY27.
International market update
Kenya operations reported revenue growth of 39 per cent year-on-year to ₹19.6 crore, driven by strong operating momentum, improving patient inflows and a better service mix.
Meanwhile, the divestment of Milann was announced in May 2026 and is expected to close in Q1 FY27. Milann grew 11 per cent year-on-year to ₹15.7 crore.